Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone by Samuel Rosner, Filiz Sen, Michael Postow

Get full text

Ensuring equity in the era of HLA-restricted cancer therapeutics by Michael Postow, James W Smithy, Amanda Blouin, Lisa C Diamond

Get full text

Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition by Anne R Bass, Michael Postow, Karmela K Chan, Deanna Jannat-Khah, Nilasha Ghosh, Quan-Zhen Li, Chengsong Zhu, Greg Vitone

Get full text

434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab by Jennifer Roberts, Michael Postow, Ezra Cohen, Bartosz Chmielowski, Conor Steuer, Jerry McCarter, Nora Zizlsperger, Jeff Kutok, Brenda O’Connell, Kara Page, Halle Zhang

135 Integration of T-cell activation and tumor mutation burden predicts anti-PD-1 response by Matthew Adamow, Katherine S Panageas, Michael Postow, Margaret K Callahan, James W Smithy, Ronglai Shen, Fiona Ehrich, Colleen Maher, Jasme Lee, Xiyu Peng, Samuel A Funt, Niamh Keegan

Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma by Hayley Higgins, Abanoub Nakhla, Andrew Lotfalla, David Khalil, Parth Doshi, Vandan Thakkar, Dorsa Shirini, Maria Bebawy, Samy Ammari, Egesta Lopci, Lawrence H. Schwartz, Michael Postow, Laurent Dercle

Get full text

The Great Debate at “Melanoma Bridge”, Naples, December 7th, 2019 by Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caracò, Alessandro Testori

Get full text

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis by Isabella Sala, Isabella Sala, Eleonora Pagan, Laura Pala, Chiara Oriecuia, Chiara Oriecuia, Marco Musca, Marco Musca, Claudia Specchia, Tommaso De Pas, Javier Cortes, Javier Cortes, Javier Cortes, Giuseppe Giaccone, Michael Postow, Richard D. Gelber, Vincenzo Bagnardi, Fabio Conforti, Fabio Conforti

Get full text

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker... by Antoni Ribas, Paul Chapman, Katherine S Panageas, Michael Postow, Joyson Karakunnel, Hussein Tawbi, Christine Spencer, Katy Tsai, Ramy Ibrahim, Jedd Wolchok, Theresa LaVallee, Travis J Hollmann, Alexander Shoushtari, Daniel K Wells, Margaret Callahan, Samantha Bucktrout, Claire F Friedman, Christopher R Cabanski, Pier Gherardini, Richard O Chen

Get full text